Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2

Status

Recruiting 13Active not recruiting 6Completed 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 6Adenocarcinoma 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × relugolix × Clear all
NCT05053152 2026-05-04

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NRG Oncology

Phase 2 Active not recruiting
194 enrolled
Genitourinary

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT06463457 2026-03-09

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

Emory University

Phase 2 Active not recruiting
94 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT07302451 2026-01-06

REDI-CaP

National Cancer Institute, Naples

Phase 2 Active not recruiting
50 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡